Ulta Beauty Results Beat in Q1; Raises Guidance on Reopening Optimism

© Reuters.

By Yasin Ebrahim

Investing.com – Ulta Beauty (NASDAQ:) reported on Thursday first quarter that topped analysts’ forecasts and the beauty retailer raised its full-year forecast as the reopening is expected to boost the recovery in demand.

Ulta Beauty shares gained 5% in after-hours trade following the report.

For the full-year 2021 comparable sales are forecast at between 23% to 25%, up from the previous guidance range of 15% to 17%; and EPS in a range of $11.50 to $11.95, up from prior estimate of $8.85 to $9.30. Revenue was expected to be between $7.7B to $7.8B.

Ulta Beauty announced earnings per share of $4.07 on revenue of $1.94B. Analysts polled by Investing.com anticipated EPS of $1.93 on revenue of $1.64B.

“The net sales increase during the first quarter of fiscal 2021 was primarily due to the favorable impact in the U.S. from improving consumer confidence, government stimulus payments and the easing of COVID-19 restrictions,” the company said.

Comparable sales increased 65.9%, compared with a decrease of 35.3% in the first quarter of fiscal 2020, driven by a 52.5% increase in transactions and an 8.8% increase in average ticket.

“As increasing consumer confidence, the relaxation of restrictions, and a desire for newness drive increased engagement with the beauty category, our differentiated model, combined with our ongoing efforts to create meaningful guest connections, position us well to lead through the category recovery.”

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

READ  GlaxoSmithKline, Vir Biotechnology’s Covid drug reduces hospitalisation and death

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Please enter your comment!
Please enter your name here